BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1421 related articles for article (PubMed ID: 12867608)

  • 1. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    Ribic CM; Sargent DJ; Moore MJ; Thibodeau SN; French AJ; Goldberg RM; Hamilton SR; Laurent-Puig P; Gryfe R; Shepherd LE; Tu D; Redston M; Gallinger S
    N Engl J Med; 2003 Jul; 349(3):247-57. PubMed ID: 12867608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer.
    Yang L; Sun Y; Huang XE; Yu DS; Zhou JN; Zhou X; Li DZ; Guan X
    Asian Pac J Cancer Prev; 2015; 16(4):1545-51. PubMed ID: 25743829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
    Elsaleh H; Iacopetta B
    Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.
    Carethers JM; Smith EJ; Behling CA; Nguyen L; Tajima A; Doctolero RT; Cabrera BL; Goel A; Arnold CA; Miyai K; Boland CR
    Gastroenterology; 2004 Feb; 126(2):394-401. PubMed ID: 14762775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
    Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability.
    Johnson L; Chu E
    Clin Colorectal Cancer; 2002 Nov; 2(3):146-8. PubMed ID: 12482330
    [No Abstract]   [Full Text] [Related]  

  • 9. Microsatellite instability and colorectal cancer prognosis.
    Benatti P; Gafà R; Barana D; Marino M; Scarselli A; Pedroni M; Maestri I; Guerzoni L; Roncucci L; Menigatti M; Roncari B; Maffei S; Rossi G; Ponti G; Santini A; Losi L; Di Gregorio C; Oliani C; Ponz de Leon M; Lanza G
    Clin Cancer Res; 2005 Dec; 11(23):8332-40. PubMed ID: 16322293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.
    Niv Y
    Isr Med Assoc J; 2005 Aug; 7(8):520-4. PubMed ID: 16106779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
    Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
    N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.
    Collura A; Lagrange A; Svrcek M; Marisa L; Buhard O; Guilloux A; Wanherdrick K; Dorard C; Taieb A; Saget A; Loh M; Soong R; Zeps N; Platell C; Mews A; Iacopetta B; De Thonel A; Seigneuric R; Marcion G; Chapusot C; Lepage C; Bouvier AM; Gaub MP; Milano G; Selves J; Senet P; Delarue P; Arzouk H; Lacoste C; Coquelle A; Bengrine-Lefèvre L; Tournigand C; Lefèvre JH; Parc Y; Biard DS; Fléjou JF; Garrido C; Duval A
    Gastroenterology; 2014 Feb; 146(2):401-11.e1. PubMed ID: 24512910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability in colon cancer.
    Allegra CJ; Kim G; Kirsch IR
    N Engl J Med; 2003 Oct; 349(18):1774-6; author reply 1774-6. PubMed ID: 14585950
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
    Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
    Hemminki A; Mecklin JP; Järvinen H; Aaltonen LA; Joensuu H
    Gastroenterology; 2000 Oct; 119(4):921-8. PubMed ID: 11040179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of microsatellite instability in the management of colorectal cancers.
    Buecher B; Cacheux W; Rouleau E; Dieumegard B; Mitry E; Lièvre A
    Dig Liver Dis; 2013 Jun; 45(6):441-9. PubMed ID: 23195666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
    Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
    Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
    Hamaya Y; Guarinos C; Tseng-Rogenski SS; Iwaizumi M; Das R; Jover R; Castells A; Llor X; Andreu M; Carethers JM
    PLoS One; 2015; 10(5):e0127591. PubMed ID: 25996601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
    Van Rijnsoever M; Elsaleh H; Joseph D; McCaul K; Iacopetta B
    Clin Cancer Res; 2003 Aug; 9(8):2898-903. PubMed ID: 12912934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.